Living with pneumonia can be a frightening and physically draining experience. The condition causes the air sacs in one or both lungs to fill with fluid or pus, turning the simple act of breathing into a labored struggle. A persistent cough, high fever, and shaking chills often accompany the deep fatigue that keeps patients bedridden for days or weeks. Treatment is vital not only to relieve these distressing symptoms but also to clear the infection and prevent serious complications like respiratory failure or the spread of bacteria to the bloodstream. 

Because pneumonia can be caused by bacteria, viruses, or fungi, the approach to treatment varies significantly depending on the source of the infection. A healthy young person may recover with rest and oral medication at home, while older adults or those with weakened immune systems may require hospitalization for intravenous therapy and oxygen support. Decisions regarding medication depend on the specific germ identified and the severity of symptoms (National Heart, Lung, and Blood Institute, 2022). 

Overview of treatment options for Pneumonia 

The primary goal of treating pneumonia is to cure the infection and prevent complications. For bacterial pneumonia, this means administering medication to kill the bacteria. For viral pneumonia, treatment is largely supportive, focusing on symptom relief while the immune system fights the virus, though specific antivirals are used in some cases. 

Treatment generally involves a combination of curative medications and supportive measures. Rest and hydration are universally recommended to help loosen mucus and replace fluids lost through fever. While most cases are acute and treated over a few weeks, recovery of full energy levels can take months. Medical intervention focuses on the appropriate pharmaceutical class for the specific pathogen involved. 

Medications used for Pneumonia 

Doctors prescribe medications based on the likely cause of the pneumonia and the patient’s health history. 

Antibiotics: These are the cornerstone of treatment for bacterial pneumonia. Doctors often prescribe “macrolides” like azithromycin or “fluoroquinolones” like levofloxacin for community-acquired cases. Clinical experience suggests that symptoms often begin to improve within one to three days of starting antibiotics, though the cough may persist longer. It is crucial to finish the entire course even if the patient feels better. 

Antivirals: If the pneumonia is caused by a virus, such as the flu virus (influenza) or SARS-CoV-2, antibiotics will not work. In these instances, doctors may prescribe specific antivirals like oseltamivir or remdesivir. These are most effective when started early in the illness. 

Antifungals: For rarer forms of pneumonia caused by fungi, usually in people with weakened immune systems, antifungal medications like fluconazole are required. 

Over-the-counter relievers: Medications such as acetaminophen or ibuprofen are frequently recommended to manage fever and chest pain. While they do not treat the underlying infection, they are essential for making the patient comfortable enough to rest and sleep. 

How these medications work 

The medications used for pneumonia target the invading pathogen or the body’s inflammatory response. 

Antibiotics: work by either killing the bacteria directly or stopping them from multiplying. For example, some antibiotics destroy the bacterial cell wall, causing the bacteria to burst, while others block the bacteria’s ability to make the proteins they need to survive. 

Antivirals: function by inhibiting specific enzymes that viruses need to replicate. By blocking this replication process, the medication reduces the viral load in the body, giving the immune system a better chance to overcome the infection. 

Fever reducers: work by blocking the production of prostaglandins, chemicals in the brain that signal the body to raise its temperature and register pain. Lowering the fever helps reduce the metabolic demand on the body, allowing energy to be directed toward healing. 

Side effects and safety considerations 

While necessary for recovery, pneumonia treatments carry potential side effects. 

Antibiotics: Commonly cause GI issues (nausea, diarrhea, stomach pain). Serious risk includes C. difficile infection (severe diarrhea) and allergic reactions (rash, hives). 

Antivirals: May cause nausea/vomiting; can interact with chronic medications, necessitating a full history. 

General safety: Maintain hydration, especially with fever or diarrhea. Seek immediate medical attention for difficulty breathing, blue discoloration (lips/fingernails), or confusion, as these signal dangerously low oxygen and require intensive care. 

Since everyone’s experience with the condition and its treatments can vary, working closely with a qualified healthcare provider helps ensure safe and effective care. 

References 

  1. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov 
  1. American Lung Association. https://www.lung.org 
  1. Centers for Disease Control and Prevention. https://www.cdc.gov 
  1. Mayo Clinic. https://www.mayoclinic.org 

Medications for Pneumonia

These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Pneumonia.

Found 38 Approved Drugs for Pneumonia

Trimethoprim

Brand Names
Sulfamethox-TMP, Sulfatrim, Sulfamethoxazole, Bactrim, Sulfameth

Trimethoprim

Brand Names
Sulfamethox-TMP, Sulfatrim, Sulfamethoxazole, Bactrim, Sulfameth
To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis and Proteus vulgaris. It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzaewhen a physician deems that sulfamethoxazole and trimethoprim could offer some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis jiroveci Pneumonia: For the treatment of documented Pneumocystis jiroveci pneumonia and for prophylaxis against P. jiroveci pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing P. jiroveci pneumonia. Traveler's Diarrhea in Adults: For the treatment of traveler's diarrhea due to susceptible strains of enterotoxigenic E. coli.

Azithromycin

Brand Names
Azasite, Zithromax

Azithromycin

Brand Names
Azasite, Zithromax
Azithromycin for oral suspension USP is a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications.

MethylPREDNISolone

Brand Names
Solu-Medrol MethylPREDNISolone, Solu-Medrol, Medrol

MethylPREDNISolone

Brand Names
Solu-Medrol MethylPREDNISolone, Solu-Medrol, Medrol
When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of Methylprednisolone Sodium Succinate for Injection, USP, is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.

Pentamidine

Brand Names
Pentam 300, NebuPent

Pentamidine

Brand Names
Pentam 300, NebuPent
Pentamidine Isethionate is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm3. These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive Pentamidine Isethionate via the Respirgard® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p.

Zyvox

Generic Name
Linezolid

Zyvox

Generic Name
Linezolid
Linezolid Injection is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia.
Showing 1-5 of 38
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances